Table 3.
Effects of supplementing cows with inorganic (INO; n = 11) or complexed (AAC; n = 9) trace minerals during the peripartal period on mRNA expression (log-2 scale) of genes related with inflammation response, oxidative stress, eicosanoids, transcription factors and antimicrobial peptides in endometrium tissue at +14 and +30 d after parturition
| Gene | Treatments | SEMa | P value1 | |||||
|---|---|---|---|---|---|---|---|---|
| INO | AAC | |||||||
| +14 | +30 | +14 | +30 | Treatment | Time | T × Tb | ||
| Inflammation | ||||||||
| IL10 | 4.13 | 3.83 | 5.13 | 3.72 | 0.19 | 0.04 | <0.01 | <0.01 |
| IL1B | 0.65 | -0.37 | 3.51 | -0.98 | 0.84 | 0.26 | <0.01 | <0.01 |
| IL6 | 2.12 | 2.91 | 2.88 | 2.70 | 0.23 | 0.24 | 0.15 | 0.03 |
| IL8 | 1.26 | -0.01 | 4.51 | -1.52 | 0.84 | 0.37 | <0.01 | <0.01 |
| MYD88 | 4.98 | 4.86 | 5.46 | 4.93 | 0.15 | 0.06 | 0.05 | 0.20 |
| NFKB1 | 5.06 | 5.36 | 5.41 | 5.06 | 0.16 | 0.87 | 0.90 | 0.06 |
| SAA3 | 3.10 | 2.77 | 4.88 | 2.06 | 1.00 | 0.46 | 0.15 | 0.25 |
| STAT3 | 5.05 | 5.22 | 5.69 | 5.16 | 0.19 | 0.05 | 0.40 | 0.11 |
| TLR2 | 5.05 | 4.58 | 5.87 | 4.39 | 0.28 | 0.19 | <0.01 | 0.10 |
| TLR4 | 5.24 | 4.49 | 5.69 | 3.34 | 0.18 | 0.40 | <0.01 | 0.08 |
| TNF | 4.21 | 4.60 | 5.67 | 4.32 | 0.36 | 0.11 | 0.12 | 0.01 |
| Oxidative stress | ||||||||
| NFE2L2 | 4.85 | 5.11 | 5.20 | 5.26 | 0.13 | 0.06 | 0.22 | 0.43 |
| NOS3 | 4.94 | 5.16 | 5.11 | 5.07 | 0.36 | 0.91 | 0.76 | 0.66 |
| NRROS | 5.18 | 4.62 | 5.20 | 4.87 | 0.32 | 0.68 | 0.13 | 0.70 |
| SOD1 | 5.19 | 5.04 | 5.26 | 5.28 | 0.09 | 0.09 | 0.39 | 0.30 |
| SOD2 | 4.83 | 4.13 | 5.57 | 3.83 | 0.32 | 0.44 | <0.01 | 0.12 |
| SOD3 | 4.87 | 5.27 | 5.08 | 5.16 | 0.26 | 0.85 | 0.28 | 0.45 |
| Eicosanoid synthesis | ||||||||
| ALOX5 | 4.89 | 4.83 | 5.08 | 5.14 | 0.41 | 0.51 | 0.99 | 0.88 |
| ALOX5AP | 4.86 | 4.92 | 5.33 | 4.95 | 0.38 | 0.51 | 0.60 | 0.48 |
| LTA4H | 5.07 | 5.30 | 5.24 | 5.23 | 0.10 | 0.51 | 0.30 | 0.24 |
| LTC4S | 3.91 | 3.87 | 4.35 | 3.98 | 0.42 | 0.45 | 0.62 | 0.70 |
| PLA2G4A | 4.92 | 5.39 | 5.44 | 4.96 | 0.29 | 0.86 | 0.99 | 0.13 |
| PTGDS | 5.26 | 4.94 | 5.05 | 4.87 | 0.29 | 0.63 | 0.34 | 0.77 |
| PTGES | 4.50 | 3.68 | 5.53 | 3.92 | 0.34 | 0.10 | <0.01 | 0.15 |
| PTGS2 | 3.17 | 4.32 | 4.94 | 2.85 | 0.77 | 0.83 | 0.52 | 0.04 |
| Transcription regulation | ||||||||
| PPARA | 5.09 | 5.48 | 5.20 | 5.68 | 0.21 | 0.48 | 0.02 | 0.79 |
| PPARD | 5.47 | 5.13 | 5.46 | 5.07 | 0.15 | 0.81 | 0.01 | 0.89 |
| PPARG | 4.72 | 5.17 | 4.64 | 6.03 | 0.31 | 0.21 | <0.01 | 0.11 |
| RXRA | 5.28 | 5.24 | 5.24 | 5.09 | 0.13 | 0.49 | 0.38 | 0.60 |
| Antimicrobial peptides | ||||||||
| MUC1 | 2.84 | 3.78 | 4.29 | 4.05 | 0.46 | 0.04 | 0.49 | 0.25 |
1 P values represents the probability of statistical significance for the fixed effects (treatment, time, treatment × time). Statistical differences were declared significant at P ≤ 0.05 and tendencies at P ≤ 0.10
aLargest standard error of the mean is shown
bInteraction of treatment × time